Myocardial ischemia related to ergot alkaloids: a case report and literature review
Related Experiment Videos
B S Galer1, R B Lipton, S Solomon
1Department of Neurology, Albert Einstein College of Medicine, Bronx, New York 10467.
Insights
Ergotamine tartrate and methysergide, used for headaches, can cause severe heart problems when combined. Caution is advised due to potential additive cardiac toxicity in susceptible patients.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Ergotamine tartrate and methysergide are established treatments for headaches, particularly cluster headaches.
- Both medications possess significant vasoconstrictive properties, a key aspect of their therapeutic action.
Observation:
- A case study involving a 31-year-old male patient with cluster headaches is presented.
- The patient experienced severe and prolonged myocardial ischemia after receiving combination therapy with ergotamine tartrate and methysergide.
Findings:
- A review of cardiovascular complications associated with individual agents and their combination was conducted.
- Pharmacologic similarities suggest potential additive or synergistic cardiac toxicity between ergotamine tartrate and methysergide.
Implications:
- The findings highlight the risk of serious cardiovascular events, such as myocardial ischemia, from combined use.
- Healthcare providers should exercise caution when prescribing these agents concurrently, especially in potentially vulnerable individuals.
- Further research may be warranted to fully elucidate the mechanisms and extent of combined cardiac toxicity.
Abstract:
Ergotamine tartrate and methysergide are widely used headache treatments with important vasoconstrictive properties. We report a 31-year-old man with cluster headaches who developed severe, prolonged myocardial ischemia following combination therapy with ergotamine tartrate and methysergide. We reviewed the cardiovascular complications of each agent alone and in combination. Given the pharmacologic similarity of these agents, we propose that they may have additive or synergistic cardiac toxicity, at least in vulnerable individuals. We recommend caution when these agents are used together.